167 related articles for article (PubMed ID: 38472447)
1. CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.
Yang T; Feng J; Yao R; Feng Q; Shen J
Insights Imaging; 2024 Mar; 15(1):69. PubMed ID: 38472447
[TBL] [Abstract][Full Text] [Related]
2. A Novel Radiomics Nomogram for the Prediction of Secondary Loss of Response to Infliximab in Crohn's Disease.
Chen Y; Li H; Feng J; Suo S; Feng Q; Shen J
J Inflamm Res; 2021; 14():2731-2740. PubMed ID: 34194236
[TBL] [Abstract][Full Text] [Related]
3. A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn's disease patients treated with infliximab.
Zhu C; Hu J; Wang X; Li C; Gao Y; Li J; Ge Y; Wu X
Eur Radiol; 2022 Oct; 32(10):6628-6636. PubMed ID: 35857074
[TBL] [Abstract][Full Text] [Related]
4. CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn's disease resistant to infliximab.
Wang Y; Luo Z; Zhou Z; Zhong Y; Zhang R; Shen X; Huang L; He W; Lin J; Fang J; Huang Q; Wang H; Zhang Z; Mao R; Feng ST; Li X; Huang B; Li Z; Zhang J; Chen Z
Insights Imaging; 2024 Jan; 15(1):28. PubMed ID: 38289416
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients.
Zhu C; Wang X; Wang S; Hu J; Gao Y; Li C; Li J; Wu X
Heliyon; 2023 Apr; 9(4):e14594. PubMed ID: 37151630
[TBL] [Abstract][Full Text] [Related]
6. Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn's disease patients.
Yueying C; Jing F; Tian Y; Yuqi Q; Jun S
Biomed Pharmacother; 2021 Oct; 142():112076. PubMed ID: 34449314
[TBL] [Abstract][Full Text] [Related]
7. CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease.
Song F; Ma M; Zeng S; Shao F; Huang W; Feng Z; Rong P
Radiol Med; 2024 Feb; 129(2):175-187. PubMed ID: 37982937
[TBL] [Abstract][Full Text] [Related]
8. Infliximab response associates with radiologic findings in bio-naïve Crohn's disease.
Yueying C; Jing F; Qi F; Jun S
Eur Radiol; 2023 Aug; 33(8):5247-5257. PubMed ID: 36928565
[TBL] [Abstract][Full Text] [Related]
9. A Novel Clinical Radiomics Nomogram to Identify Crohn's Disease from Intestinal Tuberculosis.
Zhu C; Yu Y; Wang S; Wang X; Gao Y; Li C; Li J; Ge Y; Wu X
J Inflamm Res; 2021; 14():6511-6521. PubMed ID: 34887674
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn's disease.
Chen L; Kang D; Fang L; Sun M; Li M; Zhou G; Xu C; Pang Z; Ye Y; Feng B; Wu H; Lin J; Ding B; Liu C; Shi Y; Liu Z
Therap Adv Gastroenterol; 2024; 17():17562848241256237. PubMed ID: 38827646
[TBL] [Abstract][Full Text] [Related]
11. MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease.
Feng J; Feng Q; Chen Y; Yang T; Cheng S; Qiao Y; Shen J
Front Nutr; 2021; 8():773040. PubMed ID: 35047543
[TBL] [Abstract][Full Text] [Related]
12. CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: A multicentre cohort study.
Li X; Zhang N; Hu C; Lin Y; Li J; Li Z; Cui E; Shi L; Zhuang X; Li J; Lu J; Wang Y; Liu R; Yuan C; Lin H; He J; Ke D; Tang S; Zou Y; He B; Sun C; Chen M; Huang B; Mao R; Feng ST
EClinicalMedicine; 2023 Feb; 56():101805. PubMed ID: 36618894
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography-based radiomics nomogram using machine learning for predicting 1-year surgical risk after diagnosis of Crohn's disease.
Yao J; Zhou J; Zhong Y; Zhang M; Peng X; Zhao J; Liu T; Wang W; Hu P; Meng X; Zhi M
Med Phys; 2023 Jun; 50(6):3862-3872. PubMed ID: 37029097
[TBL] [Abstract][Full Text] [Related]
14. Development and multicenter validation of a CT-based radiomics signature for predicting severe COVID-19 pneumonia.
Li L; Wang L; Zeng F; Peng G; Ke Z; Liu H; Zha Y
Eur Radiol; 2021 Oct; 31(10):7901-7912. PubMed ID: 33786655
[TBL] [Abstract][Full Text] [Related]
15. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study.
Ye XQ; Cai J; Yu Q; Cao XC; Chen Y; Rao MX; Chen BL; He Y; Zeng ZR; Chen H; Lin YM; Cao Q; Chen MH; Zhang SH
Gastroenterol Rep (Oxf); 2021 Aug; 9(4):329-338. PubMed ID: 34567565
[TBL] [Abstract][Full Text] [Related]
16. CTE-Based Radiomics Models Can Identify Mucosal Healing in Patients with Crohn's Disease.
Rong C; Zhu C; He L; Hu J; Gao Y; Li C; Qian B; Li J; Wu X
Acad Radiol; 2023 Sep; 30 Suppl 1():S199-S206. PubMed ID: 37210265
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients.
Chen Y; Li H; Feng Q; Shen J
Front Pharmacol; 2021; 12():654985. PubMed ID: 33986682
[No Abstract] [Full Text] [Related]
18. Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma.
Bian Y; Guo S; Jiang H; Gao S; Shao C; Cao K; Fang X; Li J; Wang L; Ma C; Zheng J; Jin G; Lu J
Cancer Imaging; 2022 Jan; 22(1):4. PubMed ID: 34991733
[TBL] [Abstract][Full Text] [Related]
19. CT-based whole lung radiomics nomogram: a tool for identifying the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.
Lin X; Zhou T; Ni J; Li J; Guan Y; Jiang X; Zhou X; Xia Y; Xu F; Hu H; Dong Q; Liu S; Fan L
Eur Radiol; 2024 Jan; ():. PubMed ID: 38216755
[TBL] [Abstract][Full Text] [Related]
20. A CT-Based Radiomics Nomogram to Predict Complete Ablation of Pulmonary Malignancy: A Multicenter Study.
Zhang G; Yang H; Zhu X; Luo J; Zheng J; Xu Y; Zheng Y; Wei Y; Mei Z; Shao G
Front Oncol; 2022; 12():841678. PubMed ID: 35223526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
